Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus

Keyphrases

• Adenovirus 100%
• Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 100%
• Nonhuman Primate 100%
• Severe Acute Respiratory Syndrome 100%
• Neutralizing Antibodies 100%
• Human Adenovirus (HAdV) 100%
• Titer 66%
• Pre-existing Immunity 66%
• Genetic Vaccine 66%
• United States 33%
• Virus 33%
• Immunogenicity 33%
• Vaccination 33%
• Coronavirus 33%
• Specific T Cells 33%
• Cellular Response 33%
• Further Development 33%
• Human Trials 33%
• Adenovirus Vaccine 33%
• Intramuscular Injection 33%
• Natural Infection 33%
• Human Serum 33%
• Adult Humans 33%
• Humoral Response 33%
• Minimal Impact 33%
• Product-specific 33%
• Replication-deficient 33%
• Human Adenovirus Type 5 33%
• Vaccine Carrier 33%
• Chimpanzee Adenovirus 33%

Immunology and Microbiology

• Adenoviridae 100%
• Severe Acute Respiratory Syndrome Vaccine 100%
• Human Adenovirus C 100%
• SARS Coronavirus 60%
• Neutralizing Antibody 60%
• Titer 40%
• Humoral Immunity 20%
• Immunogenicity 20%
• Coronavirinae 20%
• Transgene 20%
• Severe Acute Respiratory Syndrome 20%
• Serum (Blood) 20%
• Human Adenovirus 5 20%
• T Lymphocyte Antibody 20%